ArticleInternal medicine (Tokyo, Japan)2025

In Patients Receiving Pembrolizumab, Adverse Effects on the Pituitary Gland, Heart and Kidneys Must Be Excluded.

Josef FinstererPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.